EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts

Molly Parkyn Schneider, Oliver Looker, Maria Rebelo, David S Khoury, Matthew W A Dixon, Claude Oeuvray, Brendan S Crabb, James McCarthy, Paul R Gilson

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2023.1211613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Molly Parkyn Schneider und 8 weiteren Autor:innen. Beteiligte Einrichtung: Burnet Institute, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Parasites, Antimalarials, Malaria, Falciparum. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

M5717 is a promising antimalarial drug under development that acts against multiple stages of the life cycle of Plasmodium parasites by inhibiting the translation elongation factor 2 ( Pf eEF2), thereby preventing protein synthesis. The parasite clearance profile after drug treatment in preclinical studies in mice, and clinical trials in humans showed a notable delayed clearance phenotype whereby parasite infected red blood cells (iRBCs) persisted in the bloodstream for a significant period before eventual clearance. In a normal P. falciparum infection iRBCs sequester in the deep circulation by cytoadherence, allowing them to avoid surveillance and clearance in the spleen. We found that M5717 blocks parasite modification of their host red blood cells (RBCs) by preventing synthesis of new exported proteins, rather than by directly blocking the export of these proteins into the RBC compartment. Using in vitro models, we demonstrated that M5717 treated ring/trophozoite stage iRBCs became less rigid, and cytoadhered less well compared to untreated iRBCs. This indicates that in vivo persistence of M5717 treated iRBCs in the bloodstream is likely due to reduced cytoadherence and splenic clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParasitesAntimalarialsMalaria, FalciparumHumansAnimalsMicePlasmodium falciparumErythrocytesSpleen

Stichwörter der Autor:innen

Plasmodium falciparumantimalarial compoundcytoadherenceprotein traffickingprotein translation

Substanzen

Antimalarials

Autor:innen und Institutionen

  • Burnet Institute, Melbourne, VIC, Australia.
  • QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • University of Melbourne, Melbourne, VIC, Australia.
  • Global Health Institute of Merck, Eysins, Switzerland.
  • Monash University, Melbourne, VIC, Australia.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Parkyn Schneider, M., Looker, O., Rebelo, M., Khoury, D. S., Dixon, M. W. A., Oeuvray, C., Crabb, B. S., McCarthy, J., & Gilson, P. R. (2023). The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1211613

Vancouver

Parkyn Schneider M, Looker O, Rebelo M, Khoury DS, Dixon MWA, Oeuvray C, et al. The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1211613

BibTeX
@article{ParkynSchneider2023,
  author = {Parkyn Schneider, Molly and Looker, Oliver and Rebelo, Maria and Khoury, David S and Dixon, Matthew W A and Oeuvray, Claude and Crabb, Brendan S and McCarthy, James and Gilson, Paul R},
  title = {The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1211613}
}
Kostenlos starten →